Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease.

Wellens J., Edmans M., Obolski U., McGregor CG., Simmonds P., Turner M., Jarvis L., Skelly D., Dunachie S., Barnes E., Eyre DW., Colombel J-F., Wong S-Y., Klenerman P., Lindsay JO., Satsangi J., Thompson CP.

DOI

10.1136/gutjnl-2021-326312

Type

Journal article

Journal

Gut

Publication Date

09/2022

Volume

71

Pages

1919 - 1922

Addresses

Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.

Keywords

Humans, Inflammatory Bowel Diseases, Immunoglobulin A, Antibodies, Monoclonal, Humanized, Infliximab, COVID-19, SARS-CoV-2

Permalink Original publication